(Q41269323)

28 September 2017

Estimation of serum-free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir (English)

1 reference

28 September 2017

1 reference

1 reference

4

Lynn Colletti

0 references

author name string

Dean Hickman

1

1 reference

28 September 2017

Sudthida Vasavanonda

2

1 reference

28 September 2017

George Nequist

3

1 reference

28 September 2017

Lynn Colletti

4

1 reference

28 September 2017

Warren M Kati

5

1 reference

28 September 2017

Richard Bertz

6

1 reference

28 September 2017

Ann Hsu

7

1 reference

28 September 2017

Dale J Kempf

8

1 reference

28 September 2017

language of work or name

English

0 references

publication date

1 August 2004

1 reference

Antimicrobial Agents and Chemotherapy

28 September 2017

1 reference

28 September 2017

48

1 reference

28 September 2017

8

1 reference

28 September 2017

2911-2917

1 reference

Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=478510

Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=478510

ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=478510

Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=478510

Indinavir pharmacokinetics and parmacodynamics in children with human immunodeficiency virus infection

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=478510

ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=478510

Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=478510

Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=478510

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=478510

Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=478510

In vitro effect of alpha1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=478510

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=478510

Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=478510

The inhibitory quotient. A method for interpreting minimum inhibitory concentration data

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=478510

Alpha 1-acid glycoprotein concentrations and propranolol binding in elderly patients with acute illness

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=478510

Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=478510

Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=478510

Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=478510

The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir.

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=478510

Ex vivo protein binding of clindamycin in sera with normal and elevated alpha 1-acid glycoprotein concentrations

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=478510

The relationship between ritonavir plasma trough concentration and virological and immunological response in HIV-infected children

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=478510

The utility of inhibitory quotients in determining the relative potency of protease inhibitors

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=478510

Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=478510

Relevance of plasma protein binding to antiviral activity and clinical efficacy of inhibitors of human immunodeficiency virus protease

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=478510

Reduction of the in vitro activity of A77003, an inhibitor of human immunodeficiency virus protease, by human serum alpha 1 acid glycoprotein.

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=478510

Changes in the serum protein binding of vancomycin in patients with methicillin-resistant Staphylococcus aureus infection: the role of serum alpha 1-acid glycoprotein levels.

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=478510

Indinavir plasma protein binding in HIV-1-infected adults

19 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/15273100

12 December 2020

inferred from PubMed ID database lookup

Practical implications for the interpretation of minimum plasma concentration/inhibitory concentration ratios

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/15273100

12 December 2020

inferred from PubMed ID database lookup

Pharmacokinetic parameters of protease inhibitors and the Cmin/IC50 ratio: call for consensus

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/15273100

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1128/AAC.48.8.2911-2917.2004

1 reference

release_lv3cnpnubvgxdjnt6h5e75sy44

28 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/lv3cnpnubvgxdjnt6h5e75sy44

24 November 2022

mapped directly with Wikidata item

1 reference

28 September 2017

PubMed publication ID

15273100

1 reference